The Association between the Pan-Immune-Inflammation Value and Cancer Prognosis: A systematic review and meta-analysis

Basit Öğe Kaydı
dc.authoridSaadettin Kılıçkap / 0000-0003-1637-7390en_US
dc.authorscopusidSaadettin Kılıçkap / 8665552100
dc.authorwosidSaadettin Kılıçkap / AAP-3732-2021en_US
dc.contributor.authorGüven, Deniz Can
dc.contributor.authorŞahin, Taha Koray
dc.contributor.authorErul, Enes
dc.contributor.authorKılıçkap, Saadettin
dc.contributor.authorGambichler, Thilo
dc.contributor.authorAksoy, Sercan
dc.date.accessioned2022-06-16T11:59:41Z
dc.date.available2022-06-16T11:59:41Z
dc.date.issued2022en_US
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractBackground: Prognostic scores derived from the blood count have garnered significant interest as an indirect measure of the inflammatory pressure in cancer. The recently developed pan-immune-inflammation value (PIV), an equation including the neutrophil, platelet, monocyte, and lymphocyte levels, has been evaluated in several cohorts, although with variations in the tumor types, disease stages, cut-offs, and treatments. Therefore, we evaluated the association between survival and PIV in cancer, performing a systematic review and meta-analysis. Methods: We conducted a systematic review from the Pubmed, Medline, and Embase databases to filter the published studies until 17 May 2022. The meta-analyses were performed with the generic inverse-variance method with a random-effects model. Results: Fifteen studies encompassing 4942 patients were included. In the pooled analysis of fifteen studies, the patients with higher PIV levels had significantly increased risk of death than those with lower PIV levels (HR: 2.00, 95% CI: 1.51–2.64, p < 0.001) and increased risk of progression or death (HR: 1.80, 95% CI: 1.39–2.32, p < 0.001). Analyses were consistent across several clinical scenarios, including non-metastatic or metastatic disease, different cut-offs (500, 400, and 300), and treatment with targeted therapy or immunotherapy (p < 0.001 for each). Conclusion: The available evidence demonstrates that PIV could be a prognostic biomarker in cancer. However, further research is needed to explore the promise of PIV as a prognostic biomarker in patients with non-metastatic disease or patients treated without immunotherapy or targeted therapy.en_US
dc.identifier.citationGuven DC, Sahin TK, Erul E, Kilickap S, Gambichler T, Aksoy S. The Association between the Pan-Immune-Inflammation Value and Cancer Prognosis: A Systematic Review and Meta-Analysis. Cancers (Basel). 2022 May 27;14(11):2675. doi: 10.3390/cancers14112675. PMID: 35681656; PMCID: PMC9179577.en_US
dc.identifier.doi10.3390/cancers14112675en_US
dc.identifier.issn2072-6694en_US
dc.identifier.issue11en_US
dc.identifier.pmid35681656en_US
dc.identifier.scopus2-s2.0-85130788388en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttp://doi.org/10.3390/cancers14112675
dc.identifier.urihttps://hdl.handle.net/20.500.12713/2910
dc.identifier.volume14en_US
dc.identifier.wosWOS:000809917500001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorKılıçkap, Saadettin
dc.language.isoenen_US
dc.publisherPMCen_US
dc.relation.ispartofCancersen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBiomarkeren_US
dc.subjectCanceren_US
dc.subjectImmunotherapyen_US
dc.subjectPan-Immune-Inflammation Valueen_US
dc.subjectPIVen_US
dc.subjectTargeted Therapyen_US
dc.titleThe Association between the Pan-Immune-Inflammation Value and Cancer Prognosis: A systematic review and meta-analysisen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
cancers-14-02675-v2.pdf
Boyut:
2.69 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

PubMed İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu